BeiGene opens $800m, 400,000 sq ft oncology drug manufacturing site in Hopewell, New Jersey.

BeiGene, a global oncology company, has opened a new $800m, 400,000 sq ft manufacturing site in Hopewell, New Jersey. This flagship facility is part of their aggressive strategy to deliver oncology drugs and combinations, with CEO John Oyler stating that 10 of these will reach the clinic this year. The New Jersey site will produce medicines for cancer patients and is located within the Princeton West Innovation Campus.